SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Bacopoulos Nicholas G	2. Date of Event Requiring Statement (Month/Day/Year) 3. Issuer Name and Ticker or Trading Symbol   09/04/2008 Cyclacel Pharmaceuticals, Inc.									
(Last) (First) (Middle) C/O CYCLACEL PHARMACEUTICALS, INC.						10% Owner		5. If Amendment, Date of Original Filed (Month/Day/Year)		
200 CONNELL DRIVE, SUITE 1500				Officer (give title below)	Other (specify below)		6. Individual or Joint/Group Filing (Check Applicable Line)			
(Street) BERKELEY HEIGHTS NJ 07922							X		y One Reporting Person y More than One erson	
(City) (State) (Zip)										
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Common Stock				2,500	D <sup>(1)</sup>					
Table II - Derivative Securities Beneficially Owned     (e.g., puts, calls, warrants, options, convertible securities)										
Expirat		Date Exercisable and xpiration Date /lonth/Day/Year)		3. Title and Amount of Securi Underlying Derivative Securit		4. Conver or Exer Price o	rcise	5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiratior Date	n Title		Amount or Number of Shares	Derivative Security		or Indirect (I) (Instr. 5)		

Explanation of Responses:

1. These shares of common stock are held jointly by Dr. Bacopoulos and his wife, Ms. Calypso Gounti.

<u>/s/ Nicholas G. Bacopoulos</u> \*\* Signature of Reporting Person

Date

09/08/2008

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS: That the undersigned has made, constituted and appointed, and by this instrument does make, constitute and appoint JOEL I. PAPERNIK, TODD E. MASON, AVISHEH AVINI and MERAV GERSHTENMAN, acting individually, as his or her true and lawful attorney, for him or her, and in his or her name, place and stead, to affix, as attorney-in-fact, the signature of the undersigned to any reports or filings to the Securities and Exchange Commission on or in connection with Forms 3, 4, 5 or 144 with respect to transactions or holdings by the undersigned in equity securities issued by CYCLACEL PHARMACEUTICALS, INC., a Delaware company, and to any and all amendments to such reports, giving and granting unto each such attorney-in-fact full power and authority to do and perform every act and thing whatsoever necessary to be done in the premises, as fully as the undersigned might or could do if personally present, hereby ratifying and confirming all that each such attorney-in-fact shall lawfully do or cause to be done by virtue hereof.

This Power of Attorney shall expire on the date the undersigned is no longer required to file Forms 3, 4, 5 or 144 reports with the Securities and Exchange Commission with respect to holdings of and transactions in securities issued by CYCLACEL PHARMACEUTICALS, INC., unless revoked in writing prior thereto.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 4th day of September, 2008.

<u>/s/ Nichols G. Bacopoulos</u> Nicholas G. Bacopoulos